PROGRAM CHAIR
Pasi A. Janne, MD, PhD
Dana-Farber Cancer Institute
Director, Lowe Center for Thoracic Oncology
Professor of Medicine
Harvard Medical School
Boston, MA
FACULTY PRESENTER
Helena A. Yu, MD
Research Director, Thoracic Service
Associate Attending
Memorial Sloan Kettering
New York, NY
PROGRAM OVERVIEW
This enduring educational program will help participants understand the role of HER3 biology to better manage patients with advanced non-small cell lung cancer (NSCLC), including EGFR tyrosine kinase inhibition (TKI)-resistant tumors; review HER3-targeted therapeutics available for patients with advanced NSCLC with EGFR-activating mutations; and highlight the value of multidisciplinary management of treatment-related adverse events. This enduring program combines didactic instruction with case-based discussions and animations.
TARGET AUDIENCE
This activity is designed to meet the educational needs of US-based community and academic oncologists, pathologists, pulmonologists, oncology nurse practitioners, physician assistants, oncology nurses, and clinical and board-certified oncology pharmacists to ensure confidence in the management of NSCLC.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Evaluate the role of HER3 biology in the management of advanced NSCLC and EGFR-resistant NSCLC, including the rationale for combination HER3-targeted and EGFR-targeted therapy
- Summarize the clinical development of HER3-targeted antibodies in the management of NSCLC in patients with advanced NSCLC with EGFR-activating mutations
- Recognize the importance of multidisciplinary monitoring and management strategies in the management of treatment-related adverse events in patients receiving HER3-targeted antibody-drug conjugates
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Pasi A. Janne, MD | Dr. Janne is a consultant for AstraZenea, Boehringer Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Eli Lilly Pharmaceuticals, SFJ Pharmaceuticals, Voronoi, Daiichi Sankyo, Biocartis, Novartis, Takeda Oncology, Mirati Therapeutics, Transcenta, Silicon Therapeutics, Syndax, Nuvalent, Bayer, Esai, Allorion Therapeutics, Accutar Biotech, AbbVie, Monte Rosa, Scorpion Therapeutics, Merus, Frontier Medicines, Hongyun Biotechnology, and Duality. He has received royalties from LabCorp, and has reported Stock options from Gatekeeper Pharmaceuticals. |
| Helena A. Yu, MD | Dr. Yu is a consultant for AstraZeneca, Daiichi, Janssen, Abbvie, Amgen, Taiho, Takeda, Black Diamond, Blueprint and Cullinan. She has conducted research for AstraZeneca, Daiichi, Janssen, Black Diamond, Blueprint, Cullinan, Novartis, ERASCA, and Systimmune. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Kim Farina, PhD, Medical Director, Medical and Scientific Services for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, MS, Accreditation and Outcomes Manager, for Med Learning Group, has nothing to disclose.
- Jacquelyn Sandfort, Program Coordinator for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, Vice President of Med/Sci Services & Learner Engagement for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: December 08, 2023
EXPIRATION DATE: December 08, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
